Salvianolic acid E (Sal E) was identified as a small‐molecule inhibitor of the TWF2–YAP interaction, enhancing the efficacy of sunitinib in RCC patient‐derived xenograft (PDX) models. The gene discussed is TWF2; the disease is renal cell carcinoma.